- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Personalizing Treatment Selection
A key opinion leader in dermatology explains how the presence of type 2 inflammation informs their treatment decisions for atopic dermatitis and prurigo nodularis, while also detailing additional patient-specific factors such as age, comorbidities, and disease severity that influence their therapeutic approach.
EP: 1.Navigating the Challenges of Respiratory Diseases
EP: 2.The Impact of Atopic Dermatitis and Prurigo Nodularis
EP: 3.Linking Type 2 Inflammation to Asthma and COPD
EP: 4.Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases
EP: 5.Type 2 Inflammation: The Link Between AD and PN
EP: 6.Personalizing Treatment Selection
EP: 7.Navigating Treatment Challenges in Chronic Skin Conditions
EP: 8.Role of Biologics in Dermatological Care
EP: 9.Biomarkers as Tools in Management of Type 2 Inflammation
EP: 10.Strategies to Manage Type 2 Inflammation in Respiratory Diseases
EP: 11.Addressing Unmet Needs and Emerging Agents
EP: 12.Future Directions for Type 2 Inflammation Management
EP: 13.Type 2 Inflammatory Diseases and Impact on Quality of Life
EP: 14.Type 2 Inflammation Biomarkers
EP: 15.How Type 2 Inflammation Influences Treatment Choices
EP: 16.Complications of Uncontrolled Disease and Management of Comorbidities
EP: 17.Patient Education and Emerging Therapies
EP: 18.Unmet Needs and Future Research
- How does knowing that type 2 inflammation is a cause influence your treatment selection?
- Beyond identifying the underlying cause, what other patient-specific factors (e.g., age, comorbidities, disease severity) do you consider when selecting treatment regimens for AD or PN?
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups
May 16th 2025This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.
Read More
